Minocycline: Far beyond an antibiotic

British Journal of Pharmacology

Volumn 169, Issue 2, 2013, Pages 337-352

  Garrido Mesa, N ^a   Zarzuelo, A ^a   Galvez J ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

anti inflammatory; antibiotic; immunomodulatory; minocycline; neuroprotection; tetracyclines

Indexed keywords

MINOCYCLINE; PLACEBO;

ACNE VULGARIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; AUTISM; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; BREAST CANCER; CANCER INHIBITION; DERMATITIS; DRUG EFFICACY; DRUG STRUCTURE; ENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; LUNG CANCER; LUNG METASTASIS; MELANOMA; MULTIPLE SCLEROSIS; NEOPLASM; NEUROPATHIC PAIN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PARKINSON DISEASE; PERIODONTITIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; RHEUMATOID ARTHRITIS; SEXUALLY TRANSMITTED DISEASE; SPINAL CORD INJURY; TRAUMATIC BRAIN INJURY; VIRUS INHIBITION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MINOCYCLINE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 84876893112     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12139     Document Type: Review

References (181)

1. Abdel-Salam OME, (2008). Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets 7: 321-342.
2. Agwuh KN, MacGowan A, (2006). Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58: 256-265.
3. Alano CC, Kauppinen TM, Valls AV, Swanson RA, (2006). Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A 103: 9685-9690.
4. Amin AR, Patel RN, Thakker GD, Lowenstein CJ, Attur MG, Abramson SB, (1997). Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett 410: 259-264.
5. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, et al. (2008). High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216-3226.
6. Aronson AL, (1980). Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 176: 1061-1068.
7. Arsenis C, Moak SA, Greenwald RA, (1992). Tetracyclines (TETs) inhibit the synthesis and/or activity of cartilage proteinases in vivo and in vitro. Matrix Suppl 1: 314.
8. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L, (2001). The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137: 69-73.
9. Bain S, Ramamurthy NS, Impeduglia T, Scolman S, Golub LM, Rubin C, (1997). Tetracycline prevents cancellous bone loss and maintains near-normal rates of bone formation in streptozotocin diabetic rats. Bone 21: 147-153.
10. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L, (1975). Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 8: 713-720.
11. Basegmez C, Berber L, Yalcin F, (2011). Clinical and biochemical efficacy of minocycline in nonsurgical periodontal therapy: a randomized controlled pilot study. J Clin Pharmacol 51: 915-922.
12. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, et al. (2009). Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46: 94-102.
13. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M, (2004). Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 17: 359-366.
14. Brogden RN, Speight TM, Avery GS, (1975). Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 9: 251-291.
15. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW, (2002). Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125: 1297-1308.
16. Cai Z, Zhao Y, Yao S, Bin Zhao B, (2011). Increases in β-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-κB pathway activation. Pharmacol Rep 63: 381-391.
17. Campbell JH, Burdo TH, Autissier P, Bombardier JP, Westmoreland SV, Soulas C, et al. (2011). Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS. Plos ONE 6: e18688.
18. Chen A, Muzzio IA, Malleret G, Bartsch D, Verbitsky M, Pavlidis P, et al. (2003). Inducible enhancement of memory storage and synaptic plasticity in transgenic mice expressing an inhibitor of ATF4 (CREB-2) and C/EBP proteins. Neuron 39: 655-669.
19. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6: 797-801.
20. Cho DC, Cheong JH, Yang MS, Hwang SJ, Kim JM, Kim CH, (2011). The effect of minocycline on motor neuron recovery and neuropathic pain in a rat model of spinal cord injury. J Korean Neurosurg Soc 49: 83-91.
21. Choi Y, Kim H-S, Shin KY, Kim E-M, Kim M, Kim H-S, et al. (2007). Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32: 2393-2404.
22. Colburn RW, Rickman AJ, DeLeo JA, (1999). The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp Neurol 157: 289-304.
23. Corbacella E, Lanzoni I, Ding D, Previati M, Salvi R, (2004). Minocycline attenuates gentamicin induced hair cell loss in neonatal cochlear cultures. Hear Res 197: 11-18.
24. Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, et al. (2010). Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis 7: 96-98.
25. Daoud A, Gloria CJ, Taningco G, Hammerschlag MR, Weiss S, Gelling M, et al. (2008). Minocycline treatment results in reduced oral steroid requirements in adult asthma. Allergy Asthma Proc 29: 286-294.
26. Diguet E, Rouland R, Tison F, (2003). Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease. Ann Neurol 54: 841-842.
27. Diguet E, Fernagut P-O, Wei X, Du Y, Rouland R, Gross C, et al. (2004a). Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 19: 3266-3276.
28. Diguet E, Gross CE, Tison F, Bezard E, (2004b). Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Exp Neurol 189: 1-4.
29. Domercq M, Matute C, (2004). Neuroprotection by tetracyclines. Trends Pharmacol Sci 25: 609-612.
30. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98: 14669-14674.
31. Esterly NB, Furey NL, Flanagan LE, (1978). The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 70: 51-55.
32. Esterly NB, Koransky JS, Furey NL, Trevisan M, (1984). Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol 120: 1308-1313.
33. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA, (2006). Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 97: 1314-1326.
34. Feuerstein GZ, Wang X, Barone FC, (1997). Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. Ann N Y Acad Sci 825: 179-193.
35. Follstaedt SC, Barber SA, Zink MC, (2008). Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1. J Neurovirol 14: 376-388.
36. Friedlander RM, Brown RH, Gagliardini V, Wang J, Yuan J, (1997). Inhibition of ICE slows ALS in mice. Nature 388: 31.
37. Garrido-Mesa N, Camuesco D, Arribas B, Comalada M, Bailõn E, Cueto-Sola M, et al. (2011a). The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties. Pharmacol Res 63: 308-319.
38. Garrido-Mesa N, Utrilla P, Comalada M, Zorrilla P, Garrido-Mesa J, Zarzuelo A, et al. (2011b). The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. Biochem Pharmacol 82: 1891-1900.
39. Golub L, Greenwald R, Ramamurthy N, Zucker S, Ramsammy L, McNamara T, (1992). Tetracyclines (TCs) inhibit matrix metalloproteinases (MMPs): in vivo effects in arthritic and diabetic rats and new in vitro studies. Matrix Suppl 1: 315-316.
40. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. (1983). Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodont Res 18: 516-526.
41. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR, (1991). Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2: 297-321.
42. Gomes PS, Fernandes MH, (2007). Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cells. Arch Oral Biol 52: 251-259.
43. Good ML, Hussey DL, (2003). Minocycline: stain devil? Br J Dermatol 149: 237-239.
44. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6: 1045-1053.
45. Gourine AV, Molosh AI, Poputnikov D, Bulhak A, Sjöquist P-O, Pernow J, (2005). Endothelin-1 exerts a preconditioning-like cardioprotective effect against ischaemia/reperfusion injury via the ET(A) receptor and the mitochondrial K(ATP) channel in the rat in vivo. Br J Pharmacol 144: 331-337.
46. Greenwald R, Golub LM, (1993). Tetracyclines in arthritis. J Rheumatol 20: 1990.
47. Greenwald RA, (2011). The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacol Res 64: 610-613.
48. Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, et al. (1987). Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 14: 28-32.
49. Greenwald RA, Moak SA, Ramamurthy NS, Golub LM, (1992). Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 19: 927-938.
50. Griffin MO, Fricovsky E, Ceballos G, Villarreal F, (2010). Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 299: C539-C548.
51. Hains BC, Waxman SG, (2006). Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci 26: 4308-4317.
52. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, et al. (2000). Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6: 1099-1108.
53. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. (2008). Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 5: 15.
54. Ho EL, Spudich SS, Lee E, Fuchs D, Sinclair E, Price RW, (2011). Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study. AIDS Res Ther 8: 17.
55. Holman BL, Zweiman FG, (1975). Time course of 99mTc(Sn)-tetracycline uptake in experimental acute myocardial infarction. J Nucl Med 16: 1144-1146.
56. Holman BL, Idoine J, Fliegel CP, Davis MA, Treves S, Eldh P, et al. (1973). Detection and localization of experimental myocardial infarction with 99m Tc-tetracycline. J Nucl Med 14: 595-599.
57. Hu X, Zhou X, He B, Xu C, Wu L, Cui B, et al. (2010). Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol 638: 84-89.
58. Hu X, Wu B, Wang X, Xu C, He B, Cui B, et al. (2011). Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol 654: 274-279.
59. Hua H, Li M, Luo T, Yin Y, Jiang Y, (2011). Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 68: 3853-3868.
60. Huang T-Y, Chu H-C, Lin Y-L, Ho W-H, Hou H-S, Chao Y-C, et al. (2009a). Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. Biochem Biophys Res Commun 389: 634-639.
61. Huang T-Y, Chu H-C, Lin Y-L, Lin C-K, Hsieh T-Y, Chang W-K, et al. (2009b). Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Toxicol Appl Pharmacol 237: 69-82.
62. Humbert P, Treffel P, Chapuis JF, Buchet S, Derancourt C, Agache P, (1991). The tetracyclines in dermatology. J Am Acad Dermatol 25: 691-697.
63. Hunter CL, Bachman D, Granholm A-C, (2004). Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann Neurol 56: 675-688.
64. Inoue K, Tsuda M, (2009). Microglia and neuropathic pain. Glia 57: 1469-1479.
65. Ishikawa C, Tsuda T, Konishi H, Nakagawa N, Yamanishi K, (2009). Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes. Antimicrob Agents Chemother 53: 1760-1765.
66. Joks R, Durkin HG, (2011a). Effect of tetracyclines on IgE allergic responses and asthma. Recent Pat Inflamm Allergy Drug Discov 5: 221-228.
67. Joks R, Durkin HG, (2011b). Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs. Pharmacol Res 64: 602-609.
68. Joks R, Smith-Norowitz T, Nowakowski M, Bluth MH, Durkin HG, (2010). Tetracycline-mediated IgE isotype-specific suppression of ongoing human and murine IgE responses in vivo and murine memory IgE responses induced in vitro. Int Immunol 22: 281-288.
69. Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF, (2007). Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr Drug Deliv 4: 225-231.
70. Kalish RS, Koujak S, (2004). Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations. Clin Immunol 113: 270-277.
71. Kielian T, Esen N, Liu S, Phulwani NK, Syed MM, Phillips N, et al. (2007). Minocycline modulates neuroinflammation independently of its antimicrobial activity in Staphylococcus aureus-induced brain abscess. Am J Pathol 171: 1199-1214.
72. Kirkwood KL, Cirelli JA, Rogers JE, Giannobile WV, (2007). Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 43: 294-315.
73. Klapisz-Wolikow M, Saffar JL, (1996). Minocycline impairment of both osteoid tissue removal and osteoclastic resorption in a synchronized model of remodeling in the rat. J Cell Physiol 167: 359-368.
74. Klein NC, Cunha BA, (1995). Tetracyclines. Med Clin North Am 79: 789-801.
75. Kloppenburg M, Terwiel JP, Mallée C, Breedveld FC, Dijkmans BA, (1994). Minocycline in active rheumatoid arthritis. A placebo-controlled trial. Ann N Y Acad Sci 732: 422-423.
76. Kloppenburg M, Verweij CL, Miltenburg AM, Verhoeven AJ, Daha MR, Dijkmans BA, et al. (1995). The influence of tetracyclines on T cell activation. Clin Exp Immunol 102: 635-641.
77. Kloppenburg M, Brinkman BM, de, Rooij-Dijk HH, Miltenburg AM, Daha MR, Breedveld FC, et al. (1996). The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother 40: 934-940.
78. Koistinaho J, Hökfelt T, (1997). Altered gene expression in brain ischemia. Neuroreport 8: i-viii.
79. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, et al. (2005). Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab 25: 460-467.
80. Korting HC, Schöllmann C, (2009). Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol 23: 876-882.
81. Koukoui SD, Chaudhuri A, (2007). Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome. Brain Res Rev 53: 27-38.
82. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, et al. (2005). Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54: 1559-1565.
83. Kramer PA, Chapron DJ, Benson J, Mercik SA, (1978). Tetracycline absorption in elderly patients with achlorhydria. Clin Pharmacol Ther 23: 467-472.
84. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW, (2005). Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 94: 819-827.
85. Kriz J, Nguyen MD, Julien J-P, (2002). Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10: 268-278.
86. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. (2007). Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69: 1404-1410.
87. Langevitz P, Livneh A, Bank I, Pras M, (2000). Benefits and risks of minocycline in rheumatoid arthritis. Drug Saf 22: 405-414.
88. LeBlanc BW, Zerah ML, Kadasi LM, Chai N, Saab CY, (2011). Minocycline injection in the ventral posterolateral thalamus reverses microglial reactivity and thermal hyperalgesia secondary to sciatic neuropathy. Neurosci Lett 498: 138-142.
89. Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, et al. (2005). Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115: 71-83.
90. Li M, Ona VO, Guégan C, Chen M, Jackson-Lewis V, Andrews LJ, et al. (2000). Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288: 335-339.
91. Liu W-T, Lin C-H, Hsiao M, Gean P-W, (2011). Minocycline inhibits the growth of glioma by inducing autophagy. Autophagy 7: 166-175.
92. Lokeshwar BL, (2011). Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers. Pharmacol Res 63: 146-150.
93. Luccarini I, Ballerini C, Biagioli T, Biamonte F, Bellucci A, Rosi MC, et al. (2008). Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp Neurol 211: 214-226.
94. Macfarlane SR, Sloss CM, Cameron P, Kanke T, McKenzie RC, Plevin R, (2005). The role of intracellular Ca2+ in the regulation of proteinase-activated receptor-2 mediated nuclear factor kappa B signalling in keratinocytes. Br J Pharmacol 145: 535-544.
95. Maier K, Merkler D, Gerber J, Taheri N, Kuhnert AV, Williams SK, et al. (2007). Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis 25: 514-525.
96. Markovic DS, Vinnakota K, van, Rooijen N, Kiwit J, Synowitz M, Glass R, et al. (2011). Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav Immun 25: 624-628.
97. Masumori N, Tsukamoto T, Miyao N, Kumamoto Y, Saiki I, Yoneda J, (1994). Inhibitory effect of minocycline on in vitro invasion and experimental metastasis of mouse renal adenocarcinoma. J Urol 151: 1400-1404.
98. Mei X-P, Xu H, Xie C, Ren J, Zhou Y, Zhang H, et al. (2011). Post-injury administration of minocycline: an effective treatment for nerve-injury induced neuropathic pain. Neurosci Res 70: 305-312.
99. Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, et al. (2004). Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 55: 756.
100. Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, et al. (2009). Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler 15: 1183-1194.
101. Mika J, Osikowicz M, Makuch W, Przewlocka B, (2007). Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 560: 142-149.
102. Nelson ML, (1998). Chemical and biological dynamics of tetracyclines. Adv Dent Res 12: 5-11.
103. Nessler S, Dodel R, Bittner A, Reuss S, Du Y, Hemmer B, et al. (2002). Effect of minocycline in experimental autoimmune encephalomyelitis. Ann Neurol 52: 689-690; author reply 690.
104. Nikodemova M, Duncan ID, Watters JJ, (2006). Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IκBα degradation in a stimulus-specific manner in microglia. J Neurochem 96: 314-323.
105. Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID, (2007). Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)/betaII. J Biol Chem 282: 15208-15216.
106. Niu G, Liao Z, Cai L, Wei R, Sun L, (2008). The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice. Cancer Biother Radiopharm 23: 469-476.
107. O'Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N, et al. (2009). Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14: 511-522.
108. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, et al. (1999). Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399: 263-267.
109. Owolabi SA, Saab CY, (2006). Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal horn. FEBS Lett 580: 4306-4310.
110. Pabreja K, Dua K, Sharma S, Padi SSV, Kulkarni SK, (2011). Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol 661: 15-21.
111. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, et al. (2010). Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 10: 91.
112. Park CH, Shin TK, Lee HY, Kim SJ, Lee WS, (2011). Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice. Korean J Physiol Pharmacol 15: 115.
113. Penagarikano O, Mulle JG, Warren ST, (2007). The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet 8: 109-129.
114. Perencevich M, Burakoff R, (2006). Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 12: 651-664.
115. Pinney SP, Chen HJ, Liang D, Wang X, Schwartz A, Rabbani LE, (2003). Minocycline inhibits smooth muscle cell proliferation, migration and neointima formation after arterial injury. J Cardiovasc Pharmacol 42: 469-476.
116. Popovic N, Schubart A, Goetz BD, Zhang S-C, Linington C, Duncan Ian D, (2002). Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51: 215-223.
117. Pruzanski W, Greenwald RA, Street IP, Laliberte F, Stefanski E, Vadas P, (1992). Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol 44: 1165-1170.
118. Raghavendra V, Tanga F, DeLeo Joyce A, (2003). Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 306: 624-630.
119. Ratai E-M, Bombardier JP, Joo C-G, Annamalai L, Burdo TH, Campbell J, et al. (2010). Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS. Plos ONE 5: e10523.
120. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC, (1998). Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29: 1020-1030.
121. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza-Hidalgo M, Dillmann W, et al. (2008). Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 52: 1086-1094.
122. Sacktor N, Miyahara S, Deng L, Evans S, Schifitto G, Cohen BA, et al. (2011). Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 77: 1135-1142.
123. Saganová K, Orendácová J, Cízková D, Vanický I, (2008). Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat. Neurosci Lett 433: 246-249.
124. Saikali Z, Singh G, (2003). Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs 14: 773-778.
125. Saivin S, Houin G, (1988). Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15: 355-366.
126. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM, (2001). Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48: 1393-1399; discussion 1399-1401.
127. Sapadin AN, Fleischmajer R, (2006). Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54: 258-265.
128. Scarabelli TM, Stephanou A, Pasini E, Gitti G, Townsend P, Lawrence K, et al. (2004). Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol 43: 865-874.
129. Schultz M, (2008). Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 14: 1012-1018.
130. Seabrook TJ, Jiang L, Maier M, Lemere CA, (2006). Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53: 776-782.
131. Shahzad K, Thati M, Wang H, Kashif M, Wolter J, Ranjan S, et al. (2011). Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1). Atherosclerosis 219: 74-83.
132. Si Q, Cosenza M, Kim M-O, Zhao M-L, Brownlee M, Goldstein H, et al. (2004). A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. J Neurovirol 10: 284-292.
133. Siller SS, Broadie K, (2011). Neural circuit architecture defects in a Drosophila model of fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Models Mech 4: 673-685.
134. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PAS, et al. (2003). Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 54: 186-196.
135. Soory M, (2008). A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review. Open Dent J 2: 5-12.
136. Stefansson K, Brattsand M, Roosterman D, Kempkes C, Bocheva G, Steinhoff M, et al. (2008). Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol 128: 18-25.
137. Stirling DP, (2004). Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24: 2182-2190.
138. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W, (2005). Minocycline as a neuroprotective agent. Neuroscientist 11: 308-322.
139. Stone M, Fortin PR, Pacheco-Tena C, Inman RD, (2003). Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol 30: 2112-2122.
140. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC, (2005). Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 288: F91-F97.
141. Suzuki A, Yagisawa J, Kumakura S, Tsutsui T, (2006). Effects of minocycline and doxycycline on cell survival and gene expression in human gingival and periodontal ligament cells. J Periodont Res 41: 124-131.
142. Szeto GL, Brice AK, Yang H, Barber SA, Siliciano RF, Clements JE, (2010). Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis 201: 1132-1140.
143. Tao R, Kim SH, Honbo N, Karliner JS, Alano CC, (2010). Minocycline protects cardiac myocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 56: 659-668.
144. Taylor SS, Haste NM, Ghosh G, (2005). PKR and eIF2alpha: integration of kinase dimerization, activation, and substrate docking. Cell 122: 823-825.
145. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, et al. (2004). Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A 101: 3071-3076.
146. Thomas M, Le WD, (2004). Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des 10: 679-686.
147. Thomas M, Ashizawa T, Jankovic J, (2004). Minocycline in Huntington's disease: a pilot study. Mov Disord 19: 692-695.
148. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J, (2001). Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21: 2580-2588.
149. Tikka TM, Vartiainen NE, Goldsteins G, Oja SS, Andersen PM, Marklund SL, et al. (2002). Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 125: 722-731.
150. Tilley BC, Alarcõn GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. (1995). Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 122: 81-89.
151. Tomás-Camardiel M, Rite I, Herrera AJ, de, Pablos RM, Cano J, Machado A, et al. (2004). Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 16: 190-201.
152. Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SMH, et al. (2010). Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 115: 433-443.
153. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W, (2002). Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13: 1067-1070.
154. Végh A, Parratt JR, (2002). The role of mitochondrial K(ATP) channels in antiarrhythmic effects of ischaemic preconditioning in dogs. Br J Pharmacol 137: 1107-1115.
155. Wang AL, Yu ACH, Lau LT, Lee C, Wu LM, Zhu X, et al. (2005). Minocycline inhibits LPS-induced retinal microglia activation. Neurochem Int 47: 152-158.
156. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, et al. (2003). Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A 100: 10483-10487.
157. Wells JEA, Hurlbert RJ, Fehlings MG, Yong VW, (2003). Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 126: 1628-1637.
158. White JR, Pearce FL, (1982). Characterization of chlortetracycline (aureomycin) as a calcium ionophore. Biochemistry 21: 6309-6312.
159. Whiteman M, Halliwell B, (1997). Prevention of peroxynitrite-dependent tyrosine nitration and inactivation of alpha1-antiproteinase by antibiotics. Free Radic Res 26: 49-56.
160. Wilkins A, Nikodemova M, Compston A, Duncan I, (2004). Minocycline attenuates nitric oxide-mediated neuronal and axonal destruction in vitro. Neuron Glia Biol 1: 297-305.
161. Williams D, Laughlin L, Lee Y-H, (1974). Minocycline: possible vestibular side-effects. Lancet 304: 744-746.
162. Williams S, Wakisaka A, Zeng QQ, Barnes J, Martin G, Wechter WJ, et al. (1996). Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Bone 19: 637-644.
163. Williams S, Wakisaka A, Zeng QQ, Barnes J, Seyedin S, Martin G, et al. (1998). Effect of minocycline on osteoporosis. Adv Dent Res 12: 71-75.
164. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. (2002). Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771.
165. Xue M, Mikliaeva EI, Casha S, Zygun D, Demchuk A, Yong VW, (2010). Improving outcomes of neuroprotection by minocycline: guides from cell culture and intracerebral hemorrhage in mice. Am J Pathol 176: 1193-1202.
166. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, et al. (2003). Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 74: 278-285.
167. Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang G-Y, (2004). Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res 95: 364-371.
168. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG, (2006). Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke 37: 1087-1093.
169. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM, (2004). The promise of minocycline in neurology. Lancet Neurol 3: 744-751.
170. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. (2002). The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84.
171. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J, (1998). Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95: 15769-15774.
172. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J, (1999). A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 96: 13496-13500.
173. Yu S-W, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. (2002). Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297: 259-263.
174. Yune TY, Lee JY, Jung GY, Kim SJ, Jiang MH, Kim YC, et al. (2007). Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 27: 7751-7761.
175. Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, et al. (2007). The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 13: 517-526.
176. Zemke D, Majid A, (2004). The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 27: 293-298.
177. Zernicke RF, Wohl GR, Greenwald RA, Moak SA, Leng W, Golub LM, (1997). Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis. J Rheumatol 24: 1324-1331.
178. Zhang J, Niu X, (1994). Changes of monoamines, purines and amino acids in rat striatum as measured by intercerebral microdialysis during ischemia/reperfusion. Chin Med Sci J 9: 225-229.
179. Zhu S, Stavrovskaya IG, Drozda M, Kim BYS, Ona V, Li M, et al. (2002). Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78.
180. Zhuo M, Wu G, Wu L-J, (2011). Neuronal and microglial mechanisms of neuropathic pain. Mol Brain 4: 31.
181. Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, et al. (2005). Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293: 2003-2011.